ICV will introduce Biopharma, Diagnostic and Medical Device Companies to Government Officials, Institutional Investors and Potential Partners in Beijing, Shanghai and Hong Kong.
ICV Delegation Visit Greater China 2018 will provide insights into operating throughout China and U.S. – China relations, as well as the opportunity to explore potential investment and cross-border partnering opportunities.
According to the World Health Organization, the population of individuals aged 60 or older is set to rise 90% in China to 240 million by 2020. Over this period, the healthcare sector in China will become a US$1 trillion a year business.
The Chinese market is developing rapidly, with technological breakthroughs that are driving innovation and an aggressive move towards cross-border collaboration, both for investments and licensing.
Ahead of the delegation visit, ICV will carefully curate one-on-one and group meetings based upon targeted objectives and designed to facilitate a variety of different partnering mechanisms for co-development and/or investment.
With a targeted approach and sustained investor engagement, entry into Greater China can be transformational.
Email Athena Wang at email@example.com to learn more about this tour to Beijing, Shanghai & Hong Kong to meet with gov officials, investors(USD$10-100M), and partners.